Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Apr 10;78(4):1056-1064.
doi: 10.1093/cid/ciad677.

Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023

Collaborators, Affiliations
Multicenter Study

Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023

Nathaniel M Lewis et al. Clin Infect Dis. .

Abstract

Background: Influenza circulation during the 2022-2023 season in the United States largely returned to pre-coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. Influenza A(H3N2) viruses were detected most frequently this season, predominately clade 3C.2a1b.2a, a close antigenic match to the vaccine strain.

Methods: To understand effectiveness of the 2022-2023 influenza vaccine against influenza-associated hospitalization, organ failure, and death, a multicenter sentinel surveillance network in the United States prospectively enrolled adults hospitalized with acute respiratory illness between 1 October 2022, and 28 February 2023. Using the test-negative design, vaccine effectiveness (VE) estimates against influenza-associated hospitalization, organ failures, and death were measured by comparing the odds of current-season influenza vaccination in influenza-positive case-patients and influenza-negative, SARS-CoV-2-negative control-patients.

Results: A total of 3707 patients, including 714 influenza cases (33% vaccinated) and 2993 influenza- and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative controls (49% vaccinated) were analyzed. VE against influenza-associated hospitalization was 37% (95% confidence interval [CI]: 27%-46%) and varied by age (18-64 years: 47% [30%-60%]; ≥65 years: 28% [10%-43%]), and virus (A[H3N2]: 29% [6%-46%], A[H1N1]: 47% [23%-64%]). VE against more severe influenza-associated outcomes included: 41% (29%-50%) against influenza with hypoxemia treated with supplemental oxygen; 65% (56%-72%) against influenza with respiratory, cardiovascular, or renal failure treated with organ support; and 66% (40%-81%) against influenza with respiratory failure treated with invasive mechanical ventilation.

Conclusions: During an early 2022-2023 influenza season with a well-matched influenza vaccine, vaccination was associated with reduced risk of influenza-associated hospitalization and organ failure.

Keywords: acute respiratory illness; attenuation; influenza; organ failure; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. S. B. reports participating as the DSMB chair for Hamilton Ventilators, outside the submitted work. J. C. reports receiving funding from the National Institutes of Health (NIH) and Department of Defense (DoD), and a travel grant from Fisher-Paykel, outside the submitted work. S. C. reports consulting for PureTech Health in 2021–2022 and Kiniksa Pharmaceuticals in 2022, outside the submitted work. A. D. reports participating on an advisory board for ALung Technologies and being a principal investigator (PI) for the PETAL Network, outside the submitted work. C. G. G. reports consulting fees from Merck and received research support from Campbell Alliance/Syneos Health, NIH, CDC, Food and Drug Administration (FDA), and AHRQ, outside the submitted work. M. N. G. reports receiving grant funding from NIH and AHRQ for research, honorarium for giving Medicine grand rounds at Yale and Washington Healthcare, fees for DSMB for Palm trial and Regeneron trials on monoclonal antibodies, and fees for serving on scientific advisory board for Philips Healthcare on monitoring, outside the submitted work. R. G. reports consulting for Gilead Sciences, Eli Lily, GSK, Janssen, and AbbVie, being on an advisory board for Gilead Sciences, Eli Lily, GlaxoSmithKline (GSK), and AstraZeneca, speaker bureau for Pfizer and AbbVie, and gift-in-kind to institution from Gilead Sciences, outside the submitted work. N. H. reports prior grant support from Sanofi and Quidel, and current funding from Merck, outside the submitted work. A. L. reports being a consultant for Roche on a clinical trial of baloxavir, outside the submitted work. Christopher Mallow reports medical legal consulting, outside the submitted work. I. P. reports receiving grants from NHLBI, NIGMS, and Janssen Pharmaceuticals and institutional support from Regeneron, outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Vaccine effectiveness (VE) against influenza-associated hospitalization for the 2022–2023 seasonal influenza vaccine overall and by subgroups. Abbreviation: CI, confidence interval.
Figure 2.
Figure 2.
Peak respiratory illness severity experienced during the first 28 d of hospitalization among vaccinated and unvaccinated influenza cases. Peak respiratory illness severity was classified based on a 5-level scale, including: (1) no oxygen therapy; (2) standard flow supplemental oxygen (flow rate <30 L/min); (3) high flow nasal cannula or non-invasive ventilation; (4) invasive mechanical ventilation; (5) death. Overall, vaccinated cases experienced lower peak severity than unvaccinated cases (adjusted odds ratio: 0.59 [95% CI: .50–.70]). Abbreviation: CI, confidence interval.
Figure 3.
Figure 3.
Vaccine effectiveness (VE) of the 2022–2023 seasonal influenza vaccine against influenza-associated organ failure and death outcomes. Abbreviation: CI, confidence interval.

References

    1. CDC . Fluview Past Weekly Surveillance Reports 2017–2023. Available at: https://www.cdc.gov/flu/weekly/pastreports.htm. Accessed 18 March 2023.
    1. Chung JR, Kim SS, Kondor RJ, et al. Interim estimates of 2021–22 seasonal influenza vaccine effectiveness —United States, February 2022. MMWR Morb Mortal Wkly Rep 2022; 71:365–70. - PMC - PubMed
    1. Delahoy MJ, Mortenson L, Bauman L, et al. Influenza A(H3N2) outbreak on a university campus—Michigan, October–November 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1712–4. - PMC - PubMed
    1. Tenforde MW, Patel M, Lewis NM, et al. Vaccine effectiveness against influenza A(H3N2)–associated hospitalized illness: United States. Clin Infect Dis 2022; 76:1030–7. - PMC - PubMed
    1. McLean HQ, Petrie JG, Hanson KE, et al. Interim estimates of 2022–23 seasonal influenza vaccine effectiveness—Wisconsin, October 2022–February 2023. MMWR Morb Mortal Wkly Rep 2023; 72:201–5. - PMC - PubMed

Publication types

Substances